Jason Wittes
Stock Analyst at Roth Capital
(2.62)
# 2,050
Out of 5,129 analysts
60
Total ratings
48.08%
Success rate
4.08%
Average return
Main Sectors:
Stocks Rated by Jason Wittes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRY ARS Pharmaceuticals | Initiates: Buy | $40 | $9.50 | +321.05% | 1 | Sep 4, 2025 | |
| SYK Stryker | Maintains: Buy | $405 → $456 | $363.70 | +25.38% | 11 | May 2, 2025 | |
| ALUR Allurion Technologies | Reiterates: Buy | $16 | $1.10 | +1,354.55% | 2 | Mar 21, 2025 | |
| FBIO Fortress Biotech | Reiterates: Buy | $15 → $16 | $3.67 | +335.97% | 3 | Mar 11, 2025 | |
| OFIX Orthofix Medical | Reiterates: Buy | $22 | $13.50 | +62.96% | 5 | Feb 26, 2025 | |
| IRMD IRADIMED CORPORATION | Reiterates: Buy | $60 → $72 | $103.08 | -30.15% | 3 | Feb 14, 2025 | |
| TLSI TriSalus Life Sciences | Reiterates: Buy | $11 | $4.80 | +129.17% | 2 | Jan 24, 2025 | |
| GMED Globus Medical | Maintains: Buy | $100 → $115 | $88.26 | +30.30% | 4 | Dec 17, 2024 | |
| DERM Journey Medical | Reinstates: Buy | $11 | $7.99 | +37.67% | 1 | Jun 28, 2024 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $10 | $1.06 | +843.40% | 1 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $100 | $87.67 | +14.06% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.03 | +146.31% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.51 | +1,656.78% | 2 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $22.80 | +228.95% | 2 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $13.47 | +63.33% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $120 | $95.61 | +25.51% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $206 | $135.04 | +52.55% | 1 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $145 | $212.79 | -31.86% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $23.44 | -36.01% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $10.50 | +1,804.76% | 3 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $28.82 | -9.78% | 1 | Feb 22, 2017 |
ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $9.50
Upside: +321.05%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405 → $456
Current: $363.70
Upside: +25.38%
Allurion Technologies
Mar 21, 2025
Reiterates: Buy
Price Target: $16
Current: $1.10
Upside: +1,354.55%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15 → $16
Current: $3.67
Upside: +335.97%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $13.50
Upside: +62.96%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60 → $72
Current: $103.08
Upside: -30.15%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $4.80
Upside: +129.17%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100 → $115
Current: $88.26
Upside: +30.30%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $7.99
Upside: +37.67%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.06
Upside: +843.40%
May 31, 2024
Reinstates: Buy
Price Target: $100
Current: $87.67
Upside: +14.06%
Mar 5, 2024
Reiterates: Buy
Price Target: $5
Current: $2.03
Upside: +146.31%
Feb 13, 2024
Initiates: Buy
Price Target: $9
Current: $0.51
Upside: +1,656.78%
Oct 20, 2023
Initiates: Buy
Price Target: $75
Current: $22.80
Upside: +228.95%
Oct 20, 2023
Initiates: Buy
Price Target: $22
Current: $13.47
Upside: +63.33%
Oct 20, 2023
Initiates: Neutral
Price Target: $120
Current: $95.61
Upside: +25.51%
Sep 14, 2022
Initiates: Buy
Price Target: $206
Current: $135.04
Upside: +52.55%
Jun 27, 2022
Reinstates: Buy
Price Target: $145
Current: $212.79
Upside: -31.86%
Mar 3, 2022
Initiates: Buy
Price Target: $15
Current: $23.44
Upside: -36.01%
Feb 8, 2022
Initiates: Buy
Price Target: $200
Current: $10.50
Upside: +1,804.76%
Feb 22, 2017
Initiates: Buy
Price Target: $26
Current: $28.82
Upside: -9.78%